Moderna, Inc. (NASDAQ:MRNA)

PRESS RELEASE

published on 07/02/2024 at 13:30, 1 year 10 months ago

Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
Moderna, Inc. awarded $176 million to accelerate mRNA-based pandemic influenza vaccine development through a Consortium funded by BARDA. Collaboration aims to enhance global public health preparedness

Moderna Inc. MRNA Technology BARDA Pandemic Influenza Vaccine Global Public Health
BRIEF

published on 06/28/2024 at 13:05, 1 year 10 months ago

EMA Committee Recommends Marketing Authorization for Moderna's RSV Vaccine

Moderna MRNA Vaccine RSV EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 13:00, 1 year 10 months ago

EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
Moderna, Inc. receives positive opinion from EMA CHMP for mRESVIA mRNA-1345 vaccine for RSV in adults aged 60+. The decision from the European Commission is awaited

Moderna Inc. RSV Vaccine MRESVIA EMA CHMP MRNA-1345
BRIEF

published on 06/13/2024 at 13:05, 1 year 10 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Efficacy Data
PRESS RELEASE

published on 06/13/2024 at 13:00, 1 year 10 months ago

Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
Moderna's mRNA-1283 demonstrates non-inferior COVID-19 vaccine efficacy compared to Spikevax in Phase 3 trial. Higher efficacy in adults observed. Positive interim results reported

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 Spikevax
BRIEF

published on 06/10/2024 at 12:35, 1 year 10 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1083 Influenza
PRESS RELEASE

published on 06/10/2024 at 12:30, 1 year 10 months ago

Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
Moderna's mRNA-1083 Phase 3 trial for flu and COVID combination vaccine elicits strong immune responses in adults 50+ & 65+. Promising results may reshape respiratory virus vaccination

COVID-19 Moderna Phase 3 Trial MRNA-1083 Flu
BRIEF

published on 06/07/2024 at 16:35, 1 year 10 months ago

Moderna Files FDA Application for JN.1 Targeting COVID-19 Vaccine

FDA COVID-19 Moderna Spikevax JN.1 Variant
PRESS RELEASE

published on 06/07/2024 at 16:30, 1 year 10 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
Moderna prepares to ship Spikevax 2024-2025 formula pending FDA approval for SARS-CoV-2 variant JN.1. CEO emphasizes importance of updating COVID-19 vaccines. Adverse reactions & safety info highlighted

FDA Approval COVID-19 Vaccine Moderna Spikevax 2024-2025 Adverse Reactions
BRIEF

published on 06/06/2024 at 13:05, 1 year 10 months ago

Moderna's Investigational Therapeutic for Methylmalonic Acidemia Selected by FDA for START Pilot Program

FDA Moderna MMA MRNA-3705 START Program

Published on 05/02/2026 at 21:00, 11 hours 37 minutes ago

GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 7 hours ago

Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 7 hours ago

CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 8 hours ago

Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 8 hours ago

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

View all ACCESSWIRE

Published on 05/03/2026 at 04:45, 3 hours 52 minutes ago

GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 17 hours 2 minutes ago

Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 13 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 1 day 13 hours ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 1 day 14 hours ago

Key Figures 30.04.2026

View all EQS

Published on 04/30/2026 at 20:00, 2 days 12 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 days 13 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 days 13 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 2 days 14 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 2 days 14 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News